Invention Grant
- Patent Title: Insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
-
Application No.: US16006561Application Date: 2018-06-12
-
Publication No.: US11324834B2Publication Date: 2022-05-10
- Inventor: Hugh McTavish , Arkadiusz Z. Dudek
- Applicant: IGF Oncology, LLC
- Applicant Address: US MN Pine Springs
- Assignee: IGF Oncology, LLC
- Current Assignee: IGF Oncology, LLC
- Current Assignee Address: US MN Pine Springs
- Agent Hugh McTavish
- Main IPC: A61K47/64
- IPC: A61K47/64 ; A61P35/02 ; A61K38/30 ; A61P7/00 ; A61K31/7068 ; A61K31/519
Abstract:
Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
Public/Granted literature
- US20180333501A1 INSULIN-LIKE GROWTH FACTOR-CHEMOTHERAPEPUTIC CONJUGATE FOR TREATING MYELODYSPLASTIC SYNDROME Public/Granted day:2018-11-22
Information query
IPC分类:
